Literature DB >> 8599876

Plasma alcohol concentrations in patients following paclitaxel infusion.

L K Webster1, N A Crinis, C G Morton, M J Millward.   

Abstract

Paclitaxel is formulated in 50% Cremophor El and 50% ethanol such that patients receiving paclitaxel also receive a significant amount of each of these solvents. The aim of this study was to measure the plasma alcohol levels in patients treated with paclitaxel. A total of 12 patients who were enrolled in phase II trials of non-small-cell lung cancer, breast cancer or ovarian cancer received 175 mg/m2 paclitaxel given as a 3-h infusion. Blood samples were obtained prior to and immediately following the infusion, and plasma ethanol concentrations were measured enzymatically. The dose of ethanol delivered with the paclitaxel ranged from 20.0 to 28.9 ml. No alcohol was detected in pre-dose plasma, but 8 of 12 patients had detectable levels in post-infusion plasma, with 0.033 g/dl being the highest concentration. The elimination rate of alcohol approximates the infusion rate when paclitaxel is given over 3h, resulting in low or undetectable levels in most patients. However, in patients receiving an equivalent dose of paclitaxel given as a 1-h infusion, the plasma alcohol levels will likely be high enough for significant pharmacological effects to occur.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8599876     DOI: 10.1007/s002800050419

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  7 in total

1.  Effect of acute ethanol drinking on alcohol metabolism in subjects with different ADH and ALDH genotypes.

Authors:  D Meier-Tackmann; R A Leonhardt; D P Agarwal; H W Goedde
Journal:  Alcohol       Date:  1990 Sep-Oct       Impact factor: 2.405

2.  Mathematical modelling of ethanol metabolism in normal subjects and chronic alcohol misusers.

Authors:  G D Smith; L J Shaw; P K Maini; R J Ward; T J Peters; J D Murray
Journal:  Alcohol Alcohol       Date:  1993-01       Impact factor: 2.826

3.  Measurement of cremophor EL following taxol: plasma levels sufficient to reverse drug exclusion mediated by the multidrug-resistant phenotype.

Authors:  L Webster; M Linsenmeyer; M Millward; C Morton; J Bishop; D Woodcock
Journal:  J Natl Cancer Inst       Date:  1993-10-20       Impact factor: 13.506

4.  Phase I trial of 3-hour infusion of paclitaxel with or without granulocyte colony-stimulating factor in patients with advanced cancer.

Authors:  J H Schiller; B Storer; K Tutsch; R Arzoomanian; D Alberti; C Feierabend; D Spriggs
Journal:  J Clin Oncol       Date:  1994-02       Impact factor: 44.544

5.  Paclitaxel administered by 1-hour infusion. Preliminary results of a phase I/II trial comparing two schedules.

Authors:  J D Hainsworth; F A Greco
Journal:  Cancer       Date:  1994-08-15       Impact factor: 6.860

6.  European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion.

Authors:  E A Eisenhauer; W W ten Bokkel Huinink; K D Swenerton; L Gianni; J Myles; M E van der Burg; I Kerr; J B Vermorken; K Buser; N Colombo
Journal:  J Clin Oncol       Date:  1994-12       Impact factor: 44.544

Review 7.  Taxol: the first of the taxanes, an important new class of antitumor agents.

Authors:  E K Rowinsky; N Onetto; R M Canetta; S G Arbuck
Journal:  Semin Oncol       Date:  1992-12       Impact factor: 4.929

  7 in total
  4 in total

1.  Drug-induced hallucinatory syndrome in a patient with breast cancer after paclitaxel infusion.

Authors:  L Slovacek; B Slovackova
Journal:  Support Care Cancer       Date:  2012-03-14       Impact factor: 3.603

2.  Acute transient encephalopathy after weekly paclitaxel infusion.

Authors:  Sadık Muallaoğlu; Murat Koçer; Nilüfer Güler
Journal:  Med Oncol       Date:  2011-05-27       Impact factor: 3.064

3.  Phase I trial and pharmacological study of a 3-hour paclitaxel infusion in children with refractory solid tumours: a SFOP study.

Authors:  F Doz; J C Gentet; F Pein; D Frappaz; P Chastagner; S Moretti; G Vassal; J Arditti; O V Tellingen; A Iliadis; J Catalin
Journal:  Br J Cancer       Date:  2001-03-02       Impact factor: 7.640

4.  Effect of ethanol in Paclitaxel injections on the ethanol concentration in exhaled breath.

Authors:  Tohru Aomori; Hironori Makino; Masayuki Sekizuka; Tadahiro Hashita; Takuya Araki; Keiko Iizuka; Tomonori Nakamura; Koujirou Yamamoto
Journal:  Drugs R D       Date:  2012-09-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.